bioAffinity Technologies, Inc. (BIAFW) stock
Close on Oct 30, 2026Market cap $23.58MP/E –Yield –
bioAffinity Technologies, Inc. saw revenue fall 23.2% to $5.90M over the twelve months to Jun 30, 2026. Free cash flow was -$11.56M. At the latest close the market valued the company at $23.58M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $23.58M
- P/E ratio
- –
- Price to sales
- 4.00
- Price to book
- 6.26
- Dividend yield
- –
- Free cash flow yield
- -49.03%
Fundamentals
- Revenue
- $5.90M
- Net income
- -$15.19M
- EPS, diluted
- -$8.66
- Free cash flow
- -$11.56M
- Book value per share
- $0.72
- Diluted shares
- 5M
Trading
- Next earnings
- Nov 13, 2026 (estimated, before the open)
- Previous close
- $0.24
- Open
- $0.24
- Day's range
- $0.24 – $0.24
- Average volume (20 days)
- 1,452
- Beta (5 years)
- -1.08
- 52-week range
- $2.66 – $80.70
- RSI (14 days)
- 34.0
- Volatility (1 year)
- 207.2%
- Relative volume
- 0.02×
- WACC
- 7.5%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 30, 2026. The S&P 500 is measured by the SPY fund.
| Period | BIAFW | S&P 500 | Difference | BIAFW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -23.5% | -0.9% | −22.6 pts | ||
| 3 months | +179.8% | +2.1% | +177.6 pts | ||
| Year to date | -30.1% | +11.7% | −41.7 pts | ||
| 1 year | -47.9% | +12.4% | −60.3 pts | ||
| 3 years | +380.0% | +88.6% | +291.4 pts | +68.7% | +23.5% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases bioAffinity Technologies filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- News
About bioAffinity Technologies
Services-Commercial Physical & Biological Research
bioAffinity Technologies, Inc. develops noninvasive diagnostic laboratory tests designed to detect early-stage lung cancer and other diseases of the lung. The company uses flow cytometry combined with automated analysis informed by machine learning. Its primary commercial product, CyPath Lung, analyzes cell populations in sputum, identifying cancer and cancer-related cells to help physicians assess high-risk patients with small pulmonary nodules. Through its subsidiary OncoSelect Therapeutics, the company also conducts research on targeted cancer therapies, including topical treatments for squamous cell skin cancer, while developing companion diagnostics for asthma and chronic obstructive pulmonary disease.
Company profile, executives and historybioAffinity Technologies stock: common questions
What is bioAffinity Technologies's stock price?
BIAFW closed at $0.24 on Oct 30, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $2.66 and $80.70.
What is bioAffinity Technologies's market cap?
bioAffinity Technologies was worth $23.58M at the close on Oct 30, 2026: the share price times the diluted shares outstanding.
What is BIAFW's P/E ratio?
bioAffinity Technologies lost money over fiscal 2025 (diluted EPS -$8.66), so it has no meaningful P/E ratio.
How much revenue does bioAffinity Technologies make?
bioAffinity Technologies reported revenue of $5.90M for the twelve months to Jun 30, 2026, down 23.2% from a year earlier.
Does bioAffinity Technologies pay a dividend?
No. bioAffinity Technologies has not paid a cash dividend over the last twelve months.
When does bioAffinity Technologies report earnings next?
bioAffinity Technologies is expected to report Q3 FY2026 results on Nov 13, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has BIAFW stock performed over the past year?
Including dividends, BIAFW returned -47.9% over the past year, against +12.4% for the S&P 500.
Who are bioAffinity Technologies's competitors?
Companies most similar to bioAffinity Technologies by business, industry and size include AIDX, ABSI, MXCT, FOXO, OABI.